References
- 1
Balfour ME, Yu L, Coolen LM.
Sexual behavior and sex-associated environmental cues activate the mesolimbic system
in male rats.
Neuropsychopharmacology.
2004;
29
((4))
718-730
- 2
Baptista T, Kin NM, Beaulieu S, de Baptista EA.
Obesity and related metabolic abnormalities during antipsychotic drug administration:
mechanisms, management and research perspectives.
Pharmacopsychiatry.
2002;
35
((6))
205-219
- 3
Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M. et al. .
A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight
loss in obesity.
Obes Res.
2003;
11
((6))
722-733
- 4
Gibbs JW, III, Sombati S, DeLorenzo RJ, Coulter DA.
Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured
hippocampal neurons.
Epilepsia.
2000;
41
((Suppl 1))
S10-S16
- 5
Jackson A, Mead AN, Stephens DN.
Behavioural effects of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate-receptor
antagonists and their relevance to substance abuse.
Pharmacol Ther.
2000;
88
((1))
59-76
- 6
Rubio G, Ponce G, Jimenez-Arriero MA, Palomo T, Manzanares J, Ferre F.
Effects of topiramate in the treatment of alcohol dependence.
Pharmacopsychiatry.
2004;
37
((1))
37-40
Correspondence
Y Khazaal
Département de Psychiatrie du CHUV
Echallens 9
1004 Lausanne
Switzerland
Telefon: +41/21/643 14 14
eMail: yasser.khazaal@chuv.ch
